Liraglutide and the Preservation of Pancreatic ß-Cell Function in Early Type 2 Diabetes: The LIBRA Trial

Liraglutide provides robust enhancement of ß-cell function that is sustained over 48 weeks in early T2DM but lost upon cessation of therapy (Diabetes Care)